

## **CRITICAL OUTCOME TECHNOLOGIES AND UT MD ANDERSON CANCER CENTER SIGN LETTER OF INTENT FOR PHASE 1 DEVELOPMENT OF COTI-2**

**London, Ontario (September 8th, 2014): Critical Outcome Technologies Inc. (TSX Venture: COT; OTC: COTQF) (“COTI” or the “Company”)** the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a letter of intent (“LOI”) with The University of Texas MD Anderson Cancer Center in Houston (“MD Anderson”), for the Phase 1 clinical development of the Company’s lead cancer drug candidate, COTI-2, in gynecological cancers.

“COTI-2 is selectively active in *in vivo* and *in vitro* models with abnormal TP53. This is very exciting as TP53 is one of the “big three” of critically important genes that are not directly targetable. Further, TP53 is almost universally abnormal in high-grade serous ovarian cancer, the most common and most aggressive ovarian cancer. Thus the opportunity to test COTI-2 in ovarian cancer is both timely and exciting,” said Dr. Gordon Mills Chair of Systems Biology and co-head of the Women’s Cancer Moonshot Program. Dr. Shannon Westin, Assistant Professor in Gynecologic Oncology and co-principal investigator for the COTI-2 clinical trial, noted, “We have been eagerly anticipating the opportunity to target this common molecular aberration. COTI-2 has the potential to make a huge impact on the clinical care of women with advanced and recurrent gynecologic malignancies.”

“We are looking forward to this partnership with MD Anderson and believe the collaboration will result in COTI-2 one day becoming a breakthrough therapy not only for ovarian cancer patients, but for many patients with other common cancers,” said Dr. Wayne Danter, COTI’s Chief Executive Officer. “MD Anderson ranks as one of the world’s most respected cancer centers focused on patient care, research, education, and prevention. It has the state-of-the-art facilities, technical capabilities, and expertise to successfully execute the clinical development of COTI-2. Dr. Mills and his team at MD Anderson have been conducting experiments with COTI-2 for the past 21 months and are now very familiar with its mechanism of action and we believe are in the best position to partner with us as we move the compound forward into clinical trials.”

Under the terms of the proposed agreement, the Company and MD Anderson will work together to design and conduct a first in humans (Phase 1) study with oral COTI-2 in up to 40 women with advanced gynecological cancers who have failed conventional therapy. For the purposes of the study, the term “gynecological” cancers refers to cancers of the ovary, endometrium, and cervix. The parties have negotiated a cost structure for the clinical trial that is very favorable to the Company. COTI’s contribution is estimated at approximately \$1.25 million USD with the remainder of the costs provided by MD Anderson as in kind monitoring, testing, and pharmacy capabilities. The parties anticipate that patient recruitment for the Phase 1 clinical trial will begin in early 2015. The co-principal investigators for the COTI-2 Phase 1 clinical trial will be Dr. Gordon B. Mills, Chairman, Department of Systems Biology, Wiess Distinguished University Chair in Cancer Medicine, Co-Director, Institute for Personalized Cancer Therapy at MD Anderson and Dr. Shannon Westin, MD, MPH Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine at MD Anderson.

Additional details will be communicated when the definitive agreement has been completed.

## **About The University of Texas MD Anderson Cancer Center**

The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education, and prevention. The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research, and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public. At MD Anderson, important scientific knowledge gained in the laboratory is rapidly translated to clinical care. Overall, MD Anderson's research program is considered one of the most productive efforts in the world aimed solely at cancer.

## **About Critical Outcome Technologies Inc.**

COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules – dramatically reducing the time and cost to bring new drugs to market. COTI's proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit [www.criticaloutcome.com](http://www.criticaloutcome.com) or contact:

Critical Outcome Technologies Inc.

Dr. Wayne Danter

President & CEO

Tel: 519-858-5157

Email: [wdanter@criticaloutcome.com](mailto:wdanter@criticaloutcome.com)

Heisler Communications

Trevor Heisler

Investor Relations

Tel: 416-500-8061

Email: [trevor@heislercommunications.com](mailto:trevor@heislercommunications.com)

Follow @CriticalOutcome on Twitter at <http://twitter.com/CriticalOutcome>

## **Notice to Readers**

Information contained in this press release may contain certain statements, which constitute "forward-looking statements" within the meaning of the Securities Act (Ontario) and applicable securities laws. For example, the statement, "COTI-2 has the potential to make a huge impact on the clinical care of women with advanced and recurrent gynecologic malignancies" and "... believe the collaboration will result in COTI-2 one day becoming a breakthrough therapy not only for ovarian cancer patients, but for many patients with other common cancers..." and "... parties anticipate that patient recruitment for the Phase 1 clinical trial will begin in early 2015" are forward-looking statements. Forward-looking statements by their nature are not guarantees of future performance and are based upon management's current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. Management of COTI considers the assumptions on which these forward-looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise.

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*